Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Lowery M, Wong W, Jordan E, Lee J, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold A, Yu K, Varghese A, Kelsen D, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger M, Hyman D, Klimstra D, Abou-Alfa G, Tjan C, Covington C, Maynard H, Allen P, Askan G, Leach S, Iacobuzio-Donahue C, Robson M, Offit K, Stadler Z, O’Reilly E. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal Of The National Cancer Institute 2018, 110: 1067-1074. PMID: 29506128, PMCID: PMC6186514, DOI: 10.1093/jnci/djy024.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAllelesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGerm-Line MutationHeterozygoteHumansKaplan-Meier EstimateLoss of HeterozygosityMaleMiddle AgedPancreas, ExocrinePancreatic NeoplasmsConceptsPathogenic germline alterationsExocrine pancreatic neoplasmsOverall survivalGermline testingGermline alterationsPancreatic neoplasmsHereditary cancer predisposition genesInstitutional review board-approved protocolProspective cohort of patientsTherapeutic implicationsHereditary pancreatic cancerCancer predisposition genesBoard-approved protocolResponse to platinumCohort of patientsKaplan-Meier curvesLoss of heterozygosityPotential therapeutic implicationsMedian OSPredisposition genesSomatic tumorsExocrine neoplasmsPredictive biomarkersCancer susceptibilityPancreas cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply